TNFRSF11B and in situ carcinoma: We therefore hypothesized that diabetic patients with carcinoma in situ who are on metformin therapy may present attenuated cancellous bone loss through metformin regulation of AMPK signaling in preosteoblasts, which reduces RANKL and stimulates OPG expression.